# Daniel E Johnson

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 58 papers | 5,799 citations | 22 h-index | 63 g-index |
| 63 ext. papers | 7,308 ext. citations | 8.2 avg, IF | 6.05 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 58 | NSAIDs Overcome Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models.. *Cancers*, **2022**, 14, | 6.6 | 1 |
| 57 | Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides. *Molecular Cancer Therapeutics*, **2021**, 20, 219-228 | 6.1 | 4 |
| 56 | CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers. *Molecular Cancer Research*, **2021**, 19, 14-24 | 6.6 | 4 |
| 55 | Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction. *Cell Death and Disease*, **2021**, 12, 775 | 9.8 | 1 |
| 54 | PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance. *Head and Neck*, **2021**, 43, 3364-3373 | 4.2 | 2 |
| 53 | A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. *Science*, **2021**, 374, eabf2911 | 33.3 | 6 |
| 52 | Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that Loss Contributes to Cetuximab Resistance in Head and Neck Cancer. *Molecular Cancer Therapeutics*, **2020**, 19, 1562-1571 | 6.1 | 6 |
| 51 | Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2020**, 1867, 118679 | 4.9 | 7 |
| 50 | STAT3 decoy oligonucleotide-carrying microbubbles with pulsed ultrasound for enhanced therapeutic effect in head and neck tumors. *PLoS ONE*, **2020**, 15, e0242264 | 3.7 | 5 |
| 49 | Targeting the JAK/STAT pathway in solid tumors. *Journal of Cancer Metastasis and Treatment*, **2020**, 6, | 3.8 | 17 |
| 48 | Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. *PLoS ONE*, **2020**, 15, e0227261 | 3.7 | 4 |
| 47 | Head and neck squamous cell carcinoma. *Nature Reviews Disease Primers*, **2020**, 6, 92 | 51.1 | 397 |
| 46 | NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer. *Advances in Biological Regulation*, **2020**, 75, 100653 | 6.2 | 14 |
| 45 | Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance **2020**, 15, e0227261 | | |
| 44 | Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance **2020**, 15, e0227261 | | |
| 43 | Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance **2020**, 15, e0227261 | | |
| 42 | Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance **2020**, 15, e0227261 | | |

| | | | |
|---|---|---|---|
| 41 | Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for -altered head and neck cancer. *Journal of Experimental Medicine*, **2019**, 216, 419-427 | 16.6 | 34 |
| 40 | ATR inhibition sensitizes HPV and HPV head and neck squamous cell carcinoma to cisplatin. *Oral Oncology*, **2019**, 95, 35-42 | 4.4 | 15 |
| 39 | Targeting STAT3 in Cancer with Nucleotide Therapeutics. *Cancers*, **2019**, 11, | 6.6 | 20 |
| 38 | Gene targets of sulforaphane in head and neck squamous cell carcinoma. *Molecular Medicine Reports*, **2019**, 20, 5335-5344 | 2.9 | 2 |
| 37 | Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. *Expert Opinion on Investigational Drugs*, **2019**, 28, 351-363 | 5.9 | 9 |
| 36 | New Therapies in Head and Neck Cancer. *Trends in Cancer*, **2018**, 4, 385-396 | 12.5 | 34 |
| 35 | A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. *Leukemia and Lymphoma*, **2018**, 59, 2595-2601 | 1.9 | 7 |
| 34 | Targeting the IL-6/JAK/STAT3 signalling axis in cancer. *Nature Reviews Clinical Oncology*, **2018**, 15, 234-248 | 39.4 | 975 |
| 33 | Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. *Cancer Research*, **2018**, 78, 2383-2395 | 10.1 | 20 |
| 32 | STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer. *Molecular Cancer Therapeutics*, **2018**, 17, 1917-1926 | 6.1 | 19 |
| 31 | Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. *Seminars in Radiation Oncology*, **2018**, 28, 2-11 | 5.5 | 12 |
| 30 | Signaling by cell surface death receptors: Alterations in head and neck cancer. *Advances in Biological Regulation*, **2018**, 67, 170-178 | 6.2 | 12 |
| 29 | Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor. *International Journal of Molecular Sciences*, **2018**, 19, | 6.3 | 7 |
| 28 | An update: emerging drugs to treat squamous cell carcinomas of the head and neck. *Expert Opinion on Emerging Drugs*, **2018**, 23, 283-299 | 3.7 | 21 |
| 27 | Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV Patients. *Clinical Cancer Research*, **2017**, 23, 3072-3083 | 12.9 | 33 |
| 26 | EGFR-targeted therapies in the post-genomic era. *Cancer and Metastasis Reviews*, **2017**, 36, 463-473 | 9.6 | 95 |
| 25 | Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. *Cancer Prevention Research*, **2016**, 9, 547-57 | 3.2 | 56 |
| 24 | Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. *PLoS ONE*, **2016**, 11, e0166185 | 3.7 | 3 |

| | | | |
|---|---|---|---|
| 23 | A sensible approach to targeting STAT3-mediated transcription. *Annals of Translational Medicine*, **2016**, 4, S57 | 3.2 | |
| 22 | Chemoprevention targets for tobacco-related head and neck cancer: past lessons and future directions. *Oral Oncology*, **2015**, 51, 557-64 | 4.4 | 19 |
| 21 | An ATRActive future for differentiation therapy in AML. *Blood Reviews*, **2015**, 29, 263-8 | 11.1 | 31 |
| 20 | The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. *Endocrine-Related Cancer*, **2015**, 22, T1-17 | 5.7 | 70 |
| 19 | Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. *Blood*, **2015**, 126, 3739-3739 | 2.2 | 1 |
| 18 | The Herbicide Isoproturon Induces Activation-Induced Cytidine Deaminase Expression in Germinal Center B Cells. *Blood*, **2015**, 126, 4816-4816 | 2.2 | |
| 17 | Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells. *Oral Oncology*, **2014**, 50, 120-7 | 4.4 | 18 |
| 16 | Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. *Molecular Oncology*, **2014**, 8, 1220-30 | 7.9 | 42 |
| 15 | STAT transcription factors in normal and cancer stem cells. *Advances in Biological Regulation*, **2014**, 56, 30-44 | 6.2 | 27 |
| 14 | Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. *Molecular Medicine*, **2014**, 20, 46-56 | 6.2 | 30 |
| 13 | Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. *Cancer Biology and Therapy*, **2014**, 15, 1142-52 | 4.6 | 17 |
| 12 | Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 1114-9 | 11.5 | 62 |
| 11 | Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*, **2012**, 8, 445-544 | 10.2 | 2783 |
| 10 | First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. *Cancer Discovery*, **2012**, 2, 694-705 | 24.4 | 214 |
| 9 | Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. *Clinical Cancer Research*, **2012**, 18, 4986-96 | 12.9 | 120 |
| 8 | Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit. *Chinese Journal of Cancer*, **2012**, 31, 319-26 | | 11 |
| 7 | Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. *Molecular Cancer Therapeutics*, **2009**, 8, 2211-20 | 6.1 | 45 |
| 6 | Lack of toxicity of a STAT3 decoy oligonucleotide. *Cancer Chemotherapy and Pharmacology*, **2009**, 63, 983-95 | 3.5 | 44 |

| | | | |
|---|---|---|---|
| 5 | Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis. *Advances in Enzyme Regulation*, **2008**, 48, 98-112 | | 24 |
| 4 | Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. *Molecular Pharmacology*, **2007**, 71, 1435-43 | 4.3 | 63 |
| 3 | Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 4138-43 | 11.5 | 284 |
| 2 | Characterization of caspase proteases in cytokine-dependent myeloid progenitor cells using enzyme affinity labeling. *Journal of Cellular Biochemistry*, **1999**, 73, 79-89 | 4.7 | 3 |
| 1 | Fas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease family. *Journal of Cellular Biochemistry*, **1997**, 64, 586-594 | 4.7 | 47 |